Daily Biotech Movers — 2026-09-15: Genomics Tools Get Bid While 423 of 573 Names Fall, and Last Week's Spikes Get Sold

Tuesday, September 15, 2026 was the mirror image of Monday. Across 573 tracked public biotech and life-sciences companies, 139 finished higher against 423 decliners — a 0.33-to-1 advance/decline ratio, down from Monday’s 1.31-to-1 — on a median of -1.85% and a mean of -2.10% (standard deviation 5.10%). 116 names moved at least 5%, and 143 were anomaly-flagged once volume-only spikes are included, the busiest tape in the recent set. The sector proxies fell harder than the index: XBI -2.27% and IBB -1.27% against SPY -0.46% and XLV -0.05%.

What makes the session interesting is not the drawdown but where it landed. Five of the six largest moves were give-backs rather than discoveries. Scinai Immunotherapeutics, Monday’s biggest winner at +46.99% on 23.85x volume, closed -36.89% on 0.81x volume — below-average turnover, because the spike simply lost its bid. Profusa fell -29.34% on 0.47x volume after formally disclosing a Nasdaq compliance determination that had already been reported a week earlier. Radiopharm Theranostics fell -24.38% the session after positive Phase 2b brain-metastasis imaging data. The two exceptions went the other way on real news: PDS Biotechnology +46.65% on 9.97x volume, extending the financing and licensing re-rating it began on Monday, and Bionano Genomics +17.29% on 25.20x volume — the highest volume ratio on the board — after three new peer-reviewed studies landed on top of a proposed Medicare coverage pathway. A tools-versus-therapeutics rotation, inside a broad small-cap drawdown, with last week’s low-float spikes being sold into it. That is what this synthesis covers.

The Distribution

Measure	September 15 reading
Tracked / priced	573
Directional moves	562 (139 up, 423 down)
Up / down ratio	0.33-to-1 advancers
Mean / median	-2.10% / -1.85%
Standard deviation	5.10%
Price moves of at least 5%	116
Anomaly-flagged (incl. volume-only)	143

The breadth arithmetic is stark. Monday produced 314 advancers and 240 decliners; Tuesday produced 139 and 423. The average down-move (-3.78%) more than outweighed the average up-move (+3.03%), and the standard deviation held at 5.10% — the tail did not narrow, it changed sides. The selloff was not uniform, though, and the sector table is where the rotation becomes visible. Genetics & Genomics averaged +1.40% (n=7) with a +2.49% median, Non-Pharmaceutical Biotech +1.16% (n=20), Bioinformatics +2.31% (n=4) and Cannabis-related +0.43% (n=5) were the only positive buckets of any size, while the damage concentrated in the clinical-stage drug buckets: Stem Cells/Cellular Therapy -4.29% (n=22), Drug Delivery/Formulation -3.31% (n=31), Small Molecule Pharma -2.94% (n=146), Antibodies -2.92% (n=42) and Biologics -2.48% (n=85). Devices were the relative haven: Devices — Miscellaneous -0.28% (n=26) and Devices — Surgical -0.76% (n=29) both held up far better than the drug-development complex. Two readings are artifacts rather than signals: Nanotechnology +14.92% rests on three names, and the geographic-looking buckets such as Northern California -11.80% (n=3) and NJ, NY, PA -6.00% (n=3) are categorization by location, not a sector call.

The 6 Classes of Mover Signal

Classify Tuesday’s top six and the day’s shape is explicit: two clean events on the upside, three prior-cycle give-backs on the downside, one financing-driven repricing that is really a listing-vehicle story — and a sector rotation underneath all of it.

1. Halt-release or reverse-split-adjacent. Present three times, all on the losers board, and this is the day’s defining class. SCNI (-36.89%) is a low-float unwind: the ADS-to-ordinary-share ratio moved from 1:4,000 to 1:40,000 effective August 21, 2026 — economically a one-for-ten reverse split of the ADSs taken to restore the $1.00 minimum-bid test — and Monday’s 41.1-million-share session was that compressed float being marked up, not an operating event. PFSA (-29.34%) carries the same machinery after an August 13 one-for-four reverse split and a compliance determination letter. RADX (-24.38%) prints the dilution variant: a July registered direct offering plus an Australian placement, and a September 11 general meeting that approved additional share, option and warrant issues.

2. Single-stock clinical, regulatory, commercial or strategic event. Present twice on the winning side and these were the day’s only genuinely positive catalysts. BNGO (+17.29%) combined a same-day announcement of three new peer-reviewed studies with reimbursement progress — a proposed MolDx Local Coverage Determination for genome-wide detection of copy-number alterations and structural variants in hematologic neoplasms, announced September 10 by wholly owned subsidiary Bionano Laboratories, plus a New York State approval. PDSB (+46.65%) is a financing and governance event: the initial closing of a PIPE of up to $22.3 million led by Nant Capital, with Dr. Patrick Soon-Shiong joining the board.

3. Buyout or strategic capital. Absent as a price-setting driver at the extremes. The closest thing on the board is INDP (+15.92%), which is best understood as a listed vehicle being repriced by a $24.0 million private placement rather than a company receiving a strategic premium: its Decoy20 clinical program has been discontinued, it has no active clinical development programs, and it is evaluating strategic alternatives including potential business combinations. A financing at a listing vehicle is not the same signal as strategic capital arriving at a going concern, and this synthesis does not treat it as one.

4. Sector rotation. The organising macro fact. XBI -2.27% against XLV -0.05% is small-cap biotech being sold while broad healthcare is roughly flat, and internally the capital moved toward genomics tools and sequencing platforms — Genetics & Genomics +1.40% (n=7), Bioinformatics +2.31% (n=4), Non-Pharmaceutical Biotech +1.16% (n=20) — and away from anything bucketed as clinical-stage drug development: Stem Cells/Cellular Therapy -4.29%, Drug Delivery/Formulation -3.31%, Antibodies -2.92%. A tools-led tape inside a biotech selloff is a specific posture: the market paid for revenue and reimbursement infrastructure while marking down pipeline risk.

5. Sell-the-news / prior-cycle profit-taking. The dominant explanation for large moves, present four times. SCNI (-36.89%) gave back Monday’s entire spike in a single session, with five-day momentum of just -9.4% against a -36.89% day — the classic signature of a spike unwinding rather than a trend. PFSA (-29.34%) sold a compliance letter that had already been reported on September 9, when the shares fell more than 14% on first disclosure. RADX (-24.38%) faded a September 14 release that had moved the shares only about 1.5% on the day itself. And GTBP (-22.61% on 4.29x volume) is the cleanest mirror image on the board: it was Monday’s third-largest winner at +35.08%, and it gave a large part of that back on Tuesday with five-day momentum still sitting at +71.8%.

6. Stealth accumulation / distribution. Six names cleared the sub-3%-price and 3x-volume filter, and the most informative is a distribution print: VERA (-1.12% on 4.57x volume) traded 10.5 million shares after a pre-market session that had it up as much as 14.5% at $39, then closed at $33.67 — a full reversal of an intraday gain on heavy volume is the clearest distribution signature on the tape. The rest lean quiet-and-down: PMCB (-2.47% on 7.26x), STRO (-2.07% on 4.09x), ARVN (-1.67% on 3.14x), against two flat-to-up prints in CRDF (+2.29% on 3.90x) and SOPH (+1.27% on 3.26x).

Top 3 Winners — What Drove Them

PDSB — PDS Biotechnology — +46.65% on 9.97x volume

PDS Biotechnology closed at $0.5853 on 372,180,147 shares — 9.97x its 30-day average, with five-day momentum of +95.1%, the heaviest session and the widest one-day gain on the board. The catalyst is the financing print that already drove Monday’s +35.33%, now being re-priced on its full terms: on September 14 the company announced the initial closing of a private placement of up to $22.3 million, raising roughly $11.3 million in gross proceeds in a transaction led by Nant Capital, the investment arm of NantWorks founder Dr. Patrick Soon-Shiong, who joined the board along with James Banaag Benzinga — PDS Biotech stock surges Tuesday; GlobeNewswire — PDS Biotech announces initial closing of up to $22.3 million PIPE financing; StockTitan — PDS Biotech completes $11.3M PIPE initial closing. Two terms are doing the work. NantWorks received a one-year exclusive right to negotiate a licence for PDS0101, the HPV-targeted immunotherapy, which converts the day’s move from a dilution print into a partnership option. And a further $11 million contingent tranche — $10 million from Nant Capital plus $1 million from AB Group Ltd. — unlocks only on submission to the FDA of a registrational Phase 3 protocol for PDS0301, an IL-12 fused antibody-drug conjugate, in microsatellite-stable metastatic colorectal cancer, which gives the backer a concrete milestone to fund toward Benzinga — PDS Biotech stock surges Tuesday; StockSetups — top stock movers, September 15, 2026. Signal class: Class 2 single-stock financing and governance event carrying a Class 3 strategic-capital signature. A re-rating priced on the backer, the licence option and the Phase 3 trigger — not on new clinical data.

BNGO — Bionano Genomics — +17.29% on 25.20x volume

Bionano Genomics closed at $1.56 on 39,778,938 shares — 25.20x its 30-day average, the highest volume ratio on the entire board, with five-day momentum of +30.0% and an intraday range that ran from $1.31 to $2.23 before fading into the close. The trigger is a same-day announcement of three new peer-reviewed studies demonstrating the clinical value of its optical genome mapping platform Bionano — Bionano announces three new peer-reviewed studies; Quiver — Bionano Genomics stock opinions on new peer-reviewed studies. The more consequential layer is reimbursement: on September 10 wholly owned subsidiary Bionano Laboratories announced a proposed MolDx Local Coverage Determination for genome-wide detection of copy-number alterations and structural variants in hematologic neoplasms — a direct path toward Medicare coverage for the clinical test — alongside a New York State approval, with management presenting a multi-year growth strategy at the H.C. Wainwright healthcare conference Benzinga — Bionano Genomics stock surges Tuesday; Bionano Laboratories — proposed local coverage determination for genome-wide detection. Signal class: Class 2 single-stock commercial and reimbursement event on multi-session momentum. 39.8 million shares at 25.2x normal volume is institutional participation, and the driver is payer access rather than a data readout — with the caveat that a $1.31-to-$2.23 intraday range on a $1.56 close is a tape that rejected its own high.

INDP — Indaptus Therapeutics — +15.92% on 1.36x volume

Indaptus Therapeutics closed at $3.64 on 1,960,638 shares — 1.36x its 30-day average, with five-day momentum of +96.8% — the widest momentum gap on the winners board and a seventh consecutive up session. The catalyst dates to September 8, when the company entered a stock purchase agreement for a private placement of 20,338,974 shares for aggregate gross proceeds of approximately $24.0 million, at a purchase price equal to the Nasdaq Minimum Price plus $0.015 per share; the shares rose nearly 22% when the print circulated on September 10 StockTitan — Indaptus Therapeutics SEC filings; ADVFN — Form 8-K current report; MT Newswires — Indaptus Therapeutics shares rise after entering $24 million private placement. The context matters more than the financing. Indaptus has discontinued enrolment in its Decoy20 combination study, has no active clinical development programs, is evaluating strategic alternatives including research collaborations and potential business combinations, and closed the second quarter with roughly $11.6 million in cash and short-term investments against about $0.6 million of current liabilities — after shares outstanding rose from 2.1 million to roughly 133 million during 2026 StockTitan — Indaptus Therapeutics reports second quarter 2026 financial results and corporate update; Panabee — Indaptus Therapeutics earnings Q2 2026. Signal class: Class 2 / Class 3 hybrid — financing-scale capital arriving at an issuer that has become a public listing vehicle, with the tape pricing a strategic-alternatives outcome rather than pipeline value. Flagged: the motive force is a September 8 placement and a seven-session repricing, not a clinical event.

Top 3 Losers — What Drove Them

SCNI — Scinai Immunotherapeutics — -36.89% on 0.81x volume

Scinai Immunotherapeutics closed at $1.54 on 1,430,393 shares — 0.81x its 30-day average, the largest decline of the session and the only below-average-volume print among the six biggest losers, with five-day momentum of just -9.4%. No clean same-day catalyst. This is Monday’s +46.99% session on 41,055,517 shares at 23.85x normal volume unwinding on a fraction of the participation: the ADS-to-ordinary-share ratio moved from 1:4,000 to 1:40,000 effective August 21, 2026 — economically a one-for-ten reverse split of the ADSs, taken to restore the $1.00 minimum-bid test — which compressed the traded float and re-set the price base weeks before the spike Roic AI — Scinai Immunotherapeutics stock split history; StockTitan — Scinai Immunotherapeutics news and filings. The company’s last substantive disclosure remains September 8, when it confirmed that its PC111 option and licence arrangements with PinCell expired on August 31 and that capital is being redirected to the in-house IL-17 NanoAb nanobody platform and the Scinai Biopharma Services CDMO unit StockTitan — Scinai concludes PC111 arrangements and refocuses capital on NanoAb platform and growing CDMO business. Tuesday’s session round-tripped the prior two in a single day, with the shares trading between $1.53 and $1.88 intraday before closing at the low StockInvest — Scinai Immunotherapeutics price forecast. Signal class: Class 1 / Class 5 — post-reverse-split low-float mechanics layered on a prior-cycle unwind. A -37% day on 0.81x volume means the spike lost its bid, not that sellers arrived with new information.

PFSA — Profusa — -29.34% on 0.47x volume

Profusa closed at $1.83 on 1,130,486 shares — 0.47x its 30-day average, the thinnest relative tape on the losers board, with five-day momentum of -36.5%. The same-day disclosure is a September 15 release and it is listing housekeeping rather than operating news: the company announced that on September 9 it received a Compliance Determination Letter from Nasdaq confirming it has demonstrated compliance with Listing Rule 5550(a)(2), the $1.00 minimum bid price rule, and Rule 5550(b)(1), the stockholders’ equity rule — while remaining subject to a one-year Mandatory Panel Monitor that keeps the listing under enhanced scrutiny GlobeNewswire — Profusa, Inc. receives Nasdaq compliance determination; StockTitan — Profusa meets Nasdaq bid price, equity rules; TipRanks — Profusa regains Nasdaq compliance, enters one-year monitoring. The shares had already fallen more than 14% when the determination was first reported on September 9, and Tuesday extended that slide on almost no participation, against an August 13 one-for-four reverse split, a September 18 special meeting, and a pending option agreement with G3 Vision Labs RTTNews — Profusa receives Nasdaq confirmation of compliance; shares slide; MarketChameleon — PFSA press releases; Boardroom Alpha — Profusa special meeting, September 18, 2026. Signal class: Class 5 — sell-the-news on a compliance milestone, on a thin book. A -29% day on 0.47x volume is the absence of bids in a sub-$2 issue, not an event repricing.

RADX — Radiopharm Theranostics — -24.38% on 2.75x volume

Radiopharm Theranostics closed at $1.52 on 164,335 shares — 2.75x its 30-day average, with five-day momentum of -28.3%. The catalyst is a sell-the-news reaction to the prior session’s release: on September 14 the company announced that positive interim data from the U.S. Phase 2b imaging trial of 18F-RAD101 in suspected recurrent brain metastases had been selected for a late-breaking oral presentation at the 2026 Society of Neuro-Oncology annual meeting — 93% concordance between RAD101 PET and MRI met the primary endpoint, preliminary data from 14 patients with six-month follow-up and/or biopsy showed 86% sensitivity, the program holds FDA Fast Track designation, an FDA meeting on October 1, 2026 will align a global pivotal Phase 3 protocol, and Siemens Healthineers will manufacture and distribute the agent against a U.S. brain-metastasis imaging market the company sizes at roughly $600 million with no approved PET products StockTitan — Radiopharm Theranostics selected for late-breaking oral presentation of RAD101 Phase 2b interim data; RTTNews — Radiopharm Theranostics news and reports. The shares closed that session up only about 1.5% and gave the move back with interest the following day, and the dilution backdrop is unhelpful: a July 24, 2026 concurrent US$4.1 million registered direct offering plus up to A$12.7 million (US$8.9 million) Australian placement and share purchase plan, followed by a September 11 general meeting at which all resolutions approving additional share, option and warrant issues were carried ADVFN — Radiopharm Theranostics announces concurrent US$4.1 million registered direct offering and Australian placement; StockTitan — Radiopharm investors approve new share and warrant issues; InvestingCalendar — Radiopharm Theranostics next earnings date, September 24, 2026. Signal class: Class 5 — sell-the-news into a dilution overhang. The September 14 Phase 2b release is the most recent real disclosure, and a roughly $22 million market capitalisation on 164,000 shares is a tape with no depth.

The Cross-Cutting Pattern

Tuesday was a breadth reversal with a rotation inside it. Monday’s constructive reading — 314 advancers, a positive median, healthcare rising while the S&P fell — did not survive a single session: 423 of 573 tracked names fell, the median was -1.85%, and XBI’s -2.27% was more than four times the S&P’s decline. If the day had ended there, the story would be a straight reversal of Monday’s bid. It did not, because the capital did not leave healthcare — it moved within it. XLV closed essentially flat at -0.05% while XBI fell 2.27%, and the sector buckets split cleanly: Genetics & Genomics +1.40% (n=7), Bioinformatics +2.31% (n=4) and Non-Pharmaceutical Biotech +1.16% (n=20) were bid, while Stem Cells/Cellular Therapy -4.29% (n=22), Drug Delivery/Formulation -3.31% (n=31) and the largest bucket, Small Molecule Pharma -2.94% (n=146), were sold. That is a tools-and-platform tape, not a healthcare-exit tape.

The second theme is that the day’s largest moves were mostly the prior week’s moves being unwound, and the unwinds happened on thin volume. SCNI’s -36.89% came on 0.81x normal volume; PFSA’s -29.34% came on 0.47x; RADX printed just 164,335 shares in total. Compare that with the two winners that had real news — BNGO on 25.20x volume and PDSB on 9.97x — and the discriminator is obvious. When a 37% decline occurs on below-average turnover, nobody decided anything; the marginal buyer from Monday simply stepped away. When a 17% gain occurs on 25x turnover alongside a proposed Medicare coverage determination, an institution did decide something. The same 5% threshold that flags both kinds of day produces very different signal classes, and Tuesday is a clean example of why volume has to be read before the headline.

The honest synthesis is that September 15 was a distribution day for micro-cap pipelines and an accumulation day for reimbursement-backed diagnostics infrastructure — with the caveat that five of the six largest moves traded under $2, and two of those closed below the price levels implied by their own recent capital events.

The 5 Data Points That Matter

1. % change versus the tape. With a -1.85% median, every top-six move is a company-specific gap. PDSB +46.65% is a 48.5-point gap and SCNI -36.89% a 35-point gap — the two widest on the board. BNGO +17.29% against a +1.40% Genetics & Genomics average is a 16-point outperformance inside the day’s only positive bucket, while RADX -24.38% against that same +1.40% is a 26-point divergence, which is what a company-specific event looks like when its own sector is being bought.

2. Volume ratio. The cleanest discriminator of the day. BNGO at 25.20x and PDSB at 9.97x are the only top-six names with institutional-scale turnover on the winners side; on the losers side RADX’s 2.75x is the highest, and both SCNI (0.81x) and PFSA (0.47x) printed below average. Across the wider board the anomalies were dominated by flat-to-down prints — TPST -3.68% at 21.55x, ERNA -4.45% at 10.97x, CLLS -12.02% at 8.60x, PMCB -2.47% at 7.26x, SLXN -11.78% at 6.02x — while BIAF’s -19.80% on 0.06x normal volume is the purest thin-book signature in the dataset.

3. Five-day momentum. The column is what separates a spike from a trend. INDP +96.8% into a +15.92% day and PDSB +95.1% into a +46.65% day both say Tuesday was one leg of a longer repricing rather than its opening. On the downside, SCNI’s -9.4% against a -36.89% day is the giveaway that the move is a give-back, not a trend, and GTBP’s +71.8% against a -22.61% day says the same thing in reverse — a name still carrying a large multi-session gain while printing a double-digit decline. PFSA -36.5% against -29.34% shows Tuesday extended a slide that started earlier in the week.

4. Position in range. Absolute price is doing real work at the extremes. PDSB at $0.5853, BNGO at $1.56, SCNI at $1.54, PFSA at $1.83 and RADX at $1.52 are all sub-$2, and PDSB remains below the $1.00 minimum-bid line that its own financing unit price ($0.2825) implied. INDP at $3.64 is the exception, and it is also the only top-six name whose 52-week range ($0.92 to $8.57) puts it in the middle of a two-year band rather than near a post-restructuring floor. Two range readings are split artifacts and should be ignored: SCNI’s stated 52-week low of $1.60 sits above Tuesday’s $1.54 close because the ADS ratio change reset the series in August, and PFSA’s stated 52-week high of $3,244 is a pre-reverse-split number.

5. Cash and dilution context. The balance sheets remain the real content. PDSB raised roughly $11.3 million at a $0.2825 unit price against a share count the warrants will expand, with another $11 million contingent on an FDA Phase 3 protocol submission — the day’s +47% is a vote on the backer and the trigger, not on the terms. INDP holds about $11.6 million against $0.6 million of current liabilities after a share count that went from 2.1 million to roughly 133 million in 2026, which is why its +96.8% five-day run reads as a listing-vehicle repricing. RADX carries a US$4.1 million July registered direct offering plus an Australian placement and freshly approved warrant issues against a roughly $22 million market capitalisation. PFSA is under a one-year Panel Monitor after a third reverse split in two years. BNGO reported $30.2 million of trailing revenue with a $18.4 million market capitalisation — the only name in the top six where the enterprise value is being argued with revenue rather than with cash burn.

The five-point summary: read BNGO as a real reimbursement-infrastructure re-rating on the heaviest volume on the board, and watch whether the MolDx determination converts into covered test volume; read PDSB as a backer-driven re-rating with a licensable asset and a milestone tranche attached; read INDP as a listing vehicle marked up by a placement rather than a clinical story; read SCNI and PFSA as sub-$2 low-float mechanics where the percentage moves are tick arithmetic around compliance and split events; and read RADX as positive data sold into a dilution overhang on a tape with no depth.

What This Synthesis Will and Won’t Tell You

This is a one-day reading and should be read as such. It tells you what moved and why — the 143 anomaly-flagged names, the six data-defined top movers, the class of signal behind each, and the cross-cutting pattern: a breadth reversal (139 up against 423 down, median -1.85%, XBI -2.27% versus SPY -0.46%) in which capital stayed in healthcare but rotated from clinical-stage drug development into genomics tools and reimbursement-backed diagnostics, while five of the six largest moves were prior-session spikes and compliance letters being unwound on below-average volume. It does not tell you what happens next: whether Bionano’s proposed MolDx determination becomes final coverage and converts into test volume the $18 million market cap can be built on; whether Dr. Soon-Shiong’s board seat and the one-year PDS0101 negotiation right at PDS Biotechnology turn into an actual licence, and whether the PDS0301 Phase 3 protocol reaches the FDA; whether Indaptus completes a business combination that justifies a 133-million-share count; whether Scinai’s post-ratio-change float produces a second speculative spike or simply continues to decay; whether Profusa holds the $1.00 bid through the one-year Panel Monitor and what its September 18 meeting decides; or whether Radiopharm can hold a valuation on Phase 2b data while issuing warrants into it.

The honest limits: the catalyst investigation covers the six data-defined top movers only. The rest of the volume-anomaly board — TPST -3.68% at 21.55x, ERNA -4.45% at 10.97x, CLLS -12.02% at 8.60x, PMCB -2.47% at 7.26x, SLXN -11.78% at 6.02x, TLX +8.91% at 4.71x, VERA -1.12% at 4.57x, GTBP -22.61% at 4.29x — carries stories that are noted but not deep-dived. Three of the six top movers had no same-day substantive catalyst — Scinai’s most recent disclosure is from September 8, Radiopharm’s from September 14, and Profusa’s was a compliance letter rather than operating news — and this synthesis labels them prior-cycle and mechanical rather than inventing narratives for them. One session of breadth reversal says little on its own; the contrast with Monday does. When a market gives back a 1.31-to-1 advance/decline day in a single session while keeping the S&P nearly flat, and when the only names with institutional volume are a diagnostics platform with a coverage pathway and a micro-cap with a billionaire backer, the tape is discriminating on access and sponsorship rather than on science.

---

This is editorial analysis, not investment advice. Single-day returns reflect closing prices on 2026-09-15 and will change with market conditions, clinical readouts, financing terms, and regulatory events. Microcap and clinical-stage names can experience rapid reversals; readers should review the underlying disclosures before drawing conclusions about momentum durability.

Generated 2026-09-15 PT (post-market, after the 4 PM ET close). Market data compiled from public quote and historical market-data feeds; sector categorization from public company filings and listings; company backgrounds compiled from public investor disclosures and press releases. For the prior synthesis, see Daily Biotech Movers — 2026-09-14.